Registered title, quoted from ClinicalTrials.gov
FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation
An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Sun Yat-sen Memorial Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06409637, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 5
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (5 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Histologically confirmed hepatocellular carcinoma without other non-hepatocellular carcinoma components.
Inclusion criterion 2
Eligible for chemotherapy and targeted therapy within 1-2 months after liver transplantation.
Inclusion criterion 5
Negative serum/urine pregnancy test within 7 days prior to treatment initiation for fertile women.
Inclusion criterion 8
Pregnant or lactating women (female participants must undergo pregnancy testing within 7 days prior to treatment).
Exclusion criterion 5
ECOG performance status 0-1.
Inclusion criterion 3
History of HIV infection.
Exclusion criterion 7
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06409637, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age between 18 and 75 years inclusive.
- Histologically confirmed hepatocellular carcinoma without other non-hepatocellular carcinoma components.
- ECOG performance status 0-1.
- Child-Pugh class A liver function.
- Eligible for chemotherapy and targeted therapy within 1-2 months after liver transplantation.
- Immunosuppressive regimen including calcineurin inhibitors, mycophenolate mofetil, and sirolimus.
- Adequate liver, kidney, and bone marrow function: serum albumin >28g/L, total bilirubin ≤3mg/dL (51.3 umol/l), ALT and AST ≤5 times the upper limit of normal; serum creatinine ≤1.5 times the upper limit of normal; hemoglobin >90g/L, absolute neutrophil count (ANC) >1.5×10\^9/L, platelet count >60×10\^9/L; PT-INR <1.5 or PT within normal limits +6 seconds.
- Negative serum/urine pregnancy test within 7 days prior to treatment initiation for fertile women.
- Reliable contraception must be used by all male and female participants during the trial and for six months after its completion.
- Ability to take oral medications.
- Participants must provide written informed consent.
Exclusion Criteria:
- Life expectancy less than 6 months.
- High suspicion of hepatocellular carcinoma recurrence and metastasis.
- Concurrent malignancies.
- Allergy to lenvatinib or chemotherapy drugs.
- Pregnant or lactating women (female participants must undergo pregnancy testing within 7 days prior to treatment).
- History of severe cardiovascular diseases: congestive heart failure >NYHA class 2; active coronary artery disease (myocardial infarction within 6 months prior to enrollment); severe arrhythmias requiring antiarrhythmic therapy (β-blockers or digoxin permitted); uncontrolled hypertension.
- History of HIV infection.
- Severe active clinical infections.
- Patients requiring medication for epilepsy (e.g., steroids or antiepileptic drugs).
- Patients with kidney diseases requiring dialysis.
- Drug abuse, medical conditions, psychiatric illnesses, or social status that may interfere with the participant's participation in the study or evaluation of study results.
- Patients unable to swallow oral medications, such as those with severe upper gastrointestinal obstruction requiring gastric tube feeding.
- Previous treatment with other anti-angiogenic therapies, surgery, TACE, local therapy, systemic chemotherapy, immunotherapy, etc., before liver transplantation.
- Clear evidence of main portal vein/hepatic vein tumor thrombus or inferior vena cava tumor thrombus.
- Clear evidence of lymph node metastasis.
Quoted from ClinicalTrials.gov, NCT06409637, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06409637, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.